A kind of pharmaceutical composition for treating benign prostatic hyperplasia

A technology of prostatic hyperplasia and composition, applied in the field of medicine, can solve the problems of complex chemical composition of prescriptions, and achieve the effect of inhibiting prostatic hyperplasia and good synergy.

Inactive Publication Date: 2016-04-27
重庆三峡云海药业股份有限公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The clinical use of psyllium seed formula to treat benign prostatic hyperplasia has achieved certain curative effect, but the chemical composition of the formula is complex

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of pharmaceutical composition for treating benign prostatic hyperplasia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Experimental material: plantago seed extract: plantain seed is removed from sand and impurities, crushed plantago seed into small particles, sieved, soaked with 4 times the volume of 70-75% ethanol, refluxed and extracted 4 times, concentrated extract , dried to obtain Plantaginaceae extract, for subsequent use. Alfuzosin hydrochloride was purchased from a pharmaceutical company, batch number 20131202.

[0022] Experimental animals and their groups: 56 wistar male rats with a body weight of 283±25g were randomly divided into normal control group, model group, alfuzosin group, alfuzosin and plantago ethanol extract low-dose group (low dose group), alfuzosin and plantago ethanol extract medium dose group (middle dose group), alfuzosin and plantago ethanol extract high dose group (high dose group), plantago ethanol extract group (extract group). Except for the normal control group, the rats in the other six groups were anesthetized with ether, disinfected the skin, remov...

Embodiment 1

[0029] According to methods known in the art to prepare composition tablets, each tablet contains the following ingredients:

[0030] compound composition tablet

[0031] Alfuzosin hydrochloride 1mg, plantago ethanol extract 10mg, and other pharmaceutical excipients are commonly used excipients for tablet preparation. Wherein: the weight of alfuzosin hydrochloride is calculated by alfuzosin.

[0032] Preparation process: Prepared according to the conventional preparation process of photographic agent.

Embodiment 2

[0034] Alfuzosin hydrochloride 2.5 mg, plantago ethanol extract 100 mg, and the rest of the pharmaceutical excipients are commonly used excipients for tablet preparation. Wherein: the weight of alfuzosin hydrochloride is calculated by alfuzosin.

[0035] Preparation process: Prepared according to the conventional preparation process of photographic agent.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
control rateaaaaaaaaaa
Login to view more

Abstract

The invention relates to a medicinal composition for treating benign prostatic hyperplasia. The medicinal can be tablets, capsules, granules and the like prepared from alfuzosin or pharmaceutically acceptable salt thereof with effective dosage and plantain seed alcohol extract in a mass ratio of 1:(1-10000) by the amount of alfuzosin. Pharmacological researches on the medicinal composition discover that the medicinal composition for treating benign prostatic hyperplasia has perfect treatment effect, and can remarkably inhibit benign prostatic hyperplasia of a rat subjected to orchiectomy. The alfuzosin or pharmaceutically acceptable salt and the plantain seed alcohol extract have a synergetic effect, and achieve an unexpected technical effect.

Description

technical field [0001] The invention belongs to the technical field of medicine and relates to a pharmaceutical composition for treating benign prostatic hyperplasia. Background technique [0002] Benign prostatic hyperplasia (BPH) is the most common benign disease that causes voiding disorders in middle-aged and elderly men. The main reason is the increase of age and the existence of functional testis, and the urinary obstruction caused by it has two main reasons: one is that the testosterone produced by the testis is converted into dihydrotestosterone under the action of 5α reductase, which acts on The prostate enlarges the prostate gland. The protruding gland protrudes into the bladder, compressing the urethra and causing mechanical obstruction of the bladder outlet. On the other hand, the bladder neck, posterior urethra, prostatic body, and capsule are rich in α-receptors. Due to the stimulation of mechanical obstruction, the α-receptors in the above-mentioned parts ar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/68A61P13/08A61K31/517
Inventor 栾杰
Owner 重庆三峡云海药业股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap